Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve BioPharma DiveThe base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) BioPharma Dive The base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly to buy trio of vaccine developers in $3.8bn outlayNext: FDA delays verdict on AZ breast cancer drug Related Stories Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026 Clinical Data Key pipeline drug for Lundbeck delivers in Cushing syndrome pharminent June 15, 2026
